Literature DB >> 21691304

Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle?

Jones T Nauseef1, Michael D Henry.   

Abstract

The lethal consequences of prostate cancer are related to its metastasis to other organ sites. Epithelial-to-mesenchymal transition (EMT) has received considerable attention as a conceptual paradigm to explain invasive and metastatic behavior during cancer progression. EMT is a normal physiologic process by which cells of epithelial origin convert into cells bearing mesenchymal characteristics. It has been proposed that EMT is co-opted by cancer cells during their metastatic dissemination from a primary organ to secondary sites, but the extent to which this recapitulates physiologic EMT remains uncertain. However, there is ample evidence that EMT-like states occur in, and may contribute to, prostate cancer progression and metastasis, and so has become a very active area of research. Here we review this evidence and explore recent studies that have aimed to better define the role and mechanisms of EMT in prostate cancer. While definitive evidence of something akin to physiologic EMT is still lacking in human prostate cancer, this area of research has nonetheless provided new avenues of investigation into the longstanding puzzles of metastasis, therapeutic resistance, and prognostic biomarkers.

Entities:  

Mesh:

Year:  2011        PMID: 21691304      PMCID: PMC6858788          DOI: 10.1038/nrurol.2011.85

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


  117 in total

1.  Snail is a repressor of RKIP transcription in metastatic prostate cancer cells.

Authors:  S Beach; H Tang; S Park; A S Dhillon; E T Keller; W Kolch; K C Yeung
Journal:  Oncogene       Date:  2007-10-22       Impact factor: 9.867

2.  Transforming growth factor-beta promotes invasion in tumorigenic but not in nontumorigenic human prostatic epithelial cells.

Authors:  Mingfang Ao; Karin Williams; Neil A Bhowmick; Simon W Hayward
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

3.  Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis.

Authors:  Sharanjot Saini; Shahana Majid; Soichiro Yamamura; Laura Tabatabai; Seong O Suh; Varahram Shahryari; Yi Chen; Guoren Deng; Yuichiro Tanaka; Rajvir Dahiya
Journal:  Clin Cancer Res       Date:  2010-12-15       Impact factor: 12.531

4.  VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop.

Authors:  Oscar Gonzalez-Moreno; Jon Lecanda; Jeffrey E Green; Victor Segura; Raul Catena; Diego Serrano; Alfonso Calvo
Journal:  Exp Cell Res       Date:  2009-12-16       Impact factor: 3.905

5.  Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells.

Authors:  Meng-Lei Zhu; Natasha Kyprianou
Journal:  FASEB J       Date:  2009-11-09       Impact factor: 5.191

6.  Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells.

Authors:  Tisheeka R Graham; Haiyen E Zhau; Valerie A Odero-Marah; Adeboye O Osunkoya; K Sean Kimbro; Mourad Tighiouart; Tongrui Liu; Jonathan W Simons; Ruth M O'Regan
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

7.  Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model.

Authors:  Haiyen E Zhau; Valerie Odero-Marah; Hui-Wen Lue; Takeo Nomura; Ruoxiang Wang; Gina Chu; Zhi-Ren Liu; Binhua P Zhou; Wen-Chin Huang; Leland W K Chung
Journal:  Clin Exp Metastasis       Date:  2008-06-06       Impact factor: 5.150

8.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

9.  Co-culturing human prostate carcinoma cells with hepatocytes leads to increased expression of E-cadherin.

Authors:  C C Yates; C R Shepard; D B Stolz; A Wells
Journal:  Br J Cancer       Date:  2007-04-03       Impact factor: 7.640

10.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

View more
  93 in total

1.  Clinical-Scale Cell-Surface-Marker Independent Acoustic Microfluidic Enrichment of Tumor Cells from Blood.

Authors:  Cecilia Magnusson; Per Augustsson; Andreas Lenshof; Yvonne Ceder; Thomas Laurell; Hans Lilja
Journal:  Anal Chem       Date:  2017-11-09       Impact factor: 6.986

2.  Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.

Authors:  Jiaqi Mi; Erika Hooker; Steven Balog; Hong Zeng; Daniel T Johnson; Yongfeng He; Eun-Jeong Yu; Huiqing Wu; Vien Le; Dong-Hoon Lee; Joseph Aldahl; Mark L Gonzalgo; Zijie Sun
Journal:  J Biol Chem       Date:  2018-11-06       Impact factor: 5.157

3.  Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer.

Authors:  Pawel Osmulski; Devalingam Mahalingam; Maria E Gaczynska; Joseph Liu; Susan Huang; Aaron M Horning; Chiou-Miin Wang; Ian M Thompson; Tim H-M Huang; Chun-Liang Chen
Journal:  Prostate       Date:  2014-07-25       Impact factor: 4.104

4.  A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer.

Authors:  L A Selth; R Das; S L Townley; I Coutinho; A R Hanson; M M Centenera; N Stylianou; K Sweeney; C Soekmadji; L Jovanovic; C C Nelson; A Zoubeidi; L M Butler; G J Goodall; B G Hollier; P A Gregory; W D Tilley
Journal:  Oncogene       Date:  2016-06-06       Impact factor: 9.867

5.  Tracking and Functional Characterization of Epithelial-Mesenchymal Transition and Mesenchymal Tumor Cells during Prostate Cancer Metastasis.

Authors:  Marcus Ruscetti; Bill Quach; Eman L Dadashian; David J Mulholland; Hong Wu
Journal:  Cancer Res       Date:  2015-05-06       Impact factor: 12.701

6.  Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells.

Authors:  Jia-Xuan Qiu; Zhi-Wei Zhou; Zhi-Xu He; Ruan Jin Zhao; Xueji Zhang; Lun Yang; Shu-Feng Zhou; Zong-Fu Mao
Journal:  Drug Des Devel Ther       Date:  2015-01-07       Impact factor: 4.162

7.  A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition.

Authors:  Nathan Bucay; Divya Bhagirath; Kirandeep Sekhon; Thao Yang; Shinichiro Fukuhara; Shahana Majid; Varahram Shahryari; ZLaura Tabatabai; Kirsten L Greene; Yutaka Hashimoto; Marisa Shiina; Soichiro Yamamura; Yuichiro Tanaka; Guoren Deng; Rajvir Dahiya; Sharanjot Saini
Journal:  Cell Death Differ       Date:  2017-05-12       Impact factor: 15.828

8.  Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells.

Authors:  Juliane Colditz; Benjamin Rupf; Caroline Maiwald; Aria Baniahmad
Journal:  Mol Cell Biochem       Date:  2016-08-25       Impact factor: 3.396

9.  Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.

Authors:  Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

10.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.

Authors:  Michael Ittmann; Jiaoti Huang; Enrico Radaelli; Philip Martin; Sabina Signoretti; Ruth Sullivan; Brian W Simons; Jerrold M Ward; Brian D Robinson; Gerald C Chu; Massimo Loda; George Thomas; Alexander Borowsky; Robert D Cardiff
Journal:  Cancer Res       Date:  2013-04-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.